期刊
CURRENT ONCOLOGY REPORTS
卷 21, 期 5, 页码 -出版社
SPRINGER
DOI: 10.1007/s11912-019-0791-5
关键词
Oligometastases; Metastasis directed therapy; SBRT; Prostate cancer
类别
资金
- National Institute for Health Research (NIHR) Biomedical Research Centre at the Royal Marsden NHS Foundation Trust
- Institute of Cancer Research
Purpose of ReviewSystemic therapy for patients with hormone-sensitive oligometastatic prostate cancer is non-curative and associated with toxicities. Meanwhile, this population presents unique clinical opportunities to improve outcomes, including the demonstrated benefits of radiotherapy to the primary tumor or oligometastatic sites.Recent FindingsRecently published randomized studies have demonstrated benefits with the addition of radiotherapy to the primary disease or metastatic lesions in patients with synchronous or metachronous disease. The introduction of novel PET imaging has improved the sensitivity and specificity for detecting metastatic disease and provides an opportunity to better select patients who will benefit from local therapy.SummaryThe data presented in this review supports revisiting practice guidelines for patients with hormone-sensitive metastatic prostate cancer, particularly in relation to the role of radiotherapy to the primary tumor and sites of oligometastatic disease. Future trials will aim to further establish the role of metastasis-directed therapies in metachronous, synchronous, and castrate-resistant disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据